| Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer RJ Kelly, JA Ajani, J Kuzdzal, T Zander, E Van Cutsem, G Piessen, ... New England Journal of Medicine 384 (13), 1191-1203, 2021 | 1113 | 2021 |
| Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study COVIDSurg Collaborative Anaesthesia 76 (6), 748-758, 2021 | 555* | 2021 |
| Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial D Planchard, TM Kim, J Mazieres, E Quoix, G Riely, F Barlesi, PJ Souquet, ... The Lancet Oncology 17 (5), 642-650, 2016 | 482 | 2016 |
| Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma ED Thompson, M Zahurak, A Murphy, T Cornish, N Cuka, E Abdelfatah, ... Gut 66 (5), 794-801, 2017 | 449 | 2017 |
| Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ... Journal of Thoracic Oncology 13 (12), 1930-1939, 2018 | 361 | 2018 |
| Scientific advances in lung cancer 2015 AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone, GW Warren, C Bai, ... Journal of Thoracic Oncology 11 (5), 613-638, 2016 | 341 | 2016 |
| Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial A Lopez-Chavez, A Thomas, A Rajan, M Raffeld, B Morrow, R Kelly, ... Journal of clinical oncology 33 (9), 1000-1007, 2015 | 254 | 2015 |
| Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers R Hassan, SJ Cohen, M Phillips, I Pastan, E Sharon, RJ Kelly, ... Clinical cancer research 16 (24), 6132-6138, 2010 | 238 | 2010 |
| Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin RJ Kelly, A Lopez-Chavez, D Citrin, JE Janik, JC Morris Molecular cancer 10, 1-11, 2011 | 220 | 2011 |
| Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection PA McCullough, RJ Kelly, G Ruocco, E Lerma, J Tumlin, KR Wheelan, ... The American journal of medicine 134 (1), 16-22, 2021 | 216 | 2021 |
| Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors G Giaccone, A Rajan, A Berman, RJ Kelly, E Szabo, A Lopez-Chavez, ... Journal of Clinical Oncology 29 (15), 2052-2059, 2011 | 207 | 2011 |
| A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer RJ Kelly, D Draper, CC Chen, RW Robey, WD Figg, RL Piekarz, X Chen, ... Clinical Cancer Research 17 (3), 569-580, 2011 | 206 | 2011 |
| A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, ... Clinical cancer research 18 (8), 2344-2351, 2012 | 190 | 2012 |
| Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011 YCT Shih, F Smieliauskas, DM Geynisman, RJ Kelly, TJ Smith Journal of Clinical Oncology 33 (19), 2190-2196, 2015 | 184 | 2015 |
| Thymic malignancies: from clinical management to targeted therapies RJ Kelly, I Petrini, A Rajan, Y Wang, G Giaccone Journal of clinical oncology 29 (36), 4820-4827, 2011 | 170 | 2011 |
| A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer RJ Kelly, A Thomas, A Rajan, G Chun, A Lopez-Chavez, E Szabo, ... Annals of oncology 24 (10), 2601-2606, 2013 | 168 | 2013 |
| Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): A single-arm, phase 1b–2 trial DVT Catenacci, YK Kang, H Park, HE Uronis, KW Lee, MCH Ng, ... The lancet oncology 21 (8), 1066-1076, 2020 | 166 | 2020 |
| A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas A Rajan, RJ Kelly, JB Trepel, YS Kim, SV Alarcon, S Kummar, M Gutierrez, ... Clinical Cancer Research 17 (21), 6831-6839, 2011 | 147 | 2011 |
| Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis D Planchard, B Besse, HJM Groen, SMS Hashemi, J Mazieres, TM Kim, ... Journal of Thoracic Oncology 17 (1), 103-115, 2022 | 139 | 2022 |
| Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy K Suresh, KJ Psoter, KR Voong, B Shankar, PM Forde, DS Ettinger, ... Journal of Thoracic Oncology 14 (3), 494-502, 2019 | 136 | 2019 |
